Why GeoVax Labs Stock Is Moving Higher Thursday
Portfolio Pulse from Dylan Berman
GeoVax Labs, Inc. (NASDAQ:GOVX) shares are surging due to a BARDA Project NextGen award for a Phase 2b study of its COVID-19 vaccine candidate GEO-CM04S1. The study will compare the vaccine's efficacy and safety against an FDA-approved mRNA vaccine. The award includes $24.3 million for trial preparations, potentially increasing to $45 million, with an additional $343 million for trial execution.
June 27, 2024 | 5:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GeoVax Labs shares are up 102% following a BARDA Project NextGen award for a Phase 2b study of its COVID-19 vaccine candidate GEO-CM04S1. The award includes $24.3 million for trial preparations, potentially increasing to $45 million, with an additional $343 million for trial execution.
The significant monetary award and the large-scale Phase 2b study for GeoVax's COVID-19 vaccine candidate are likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100